PMC:3724972 / 9947-10754 JSONTXT

{"target":"https://pubannotation.org/docs/sourcedb/PMC/sourceid/3724972","sourcedb":"PMC","sourceid":"3724972","source_url":"https://www.ncbi.nlm.nih.gov/pmc/3724972","text":"After promising results in a 15-day Phase 2 trial [40], a randomized, double-blind phase 3 trial of pasireotide was conducted in adult patients with de novo, persistent, or recurrent CD (UFC ≥1.5× upper limit of normal [ULN]) who were not candidates for surgery and with no pituitary radiotherapy in the preceding 10 years. Eligible patients (N = 162) were randomized to receive 600 or 900 mcg of pasireotide twice daily for an initial period of 3 months. After 3 months, those with UFC \u003cbaseline and \u003c2× ULN continued blinded therapy for another 3 months. Other patients were unblinded, and their dose was increased by 300 mcg twice daily. At 6 months, all patients entered the open-label phase of the study and could have their dose increased again to a maximum of 1200 mcg twice daily, if necessary [43].","tracks":[{"project":"2_test","denotations":[{"id":"23673515-18957506-63233621","span":{"begin":51,"end":53},"obj":"18957506"},{"id":"23673515-22397653-63233622","span":{"begin":803,"end":805},"obj":"22397653"}],"attributes":[{"subj":"23673515-18957506-63233621","pred":"source","obj":"2_test"},{"subj":"23673515-22397653-63233622","pred":"source","obj":"2_test"}]}],"config":{"attribute types":[{"pred":"source","value type":"selection","values":[{"id":"2_test","color":"#ecc493","default":true}]}]}}